These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 26669919)

  • 1. Safety and Efficacy of Open-label Subcutaneous Ixekizumab Treatment for 48 Weeks in a Phase II Study in Biologic-naive and TNF-IR Patients with Rheumatoid Arthritis.
    Genovese MC; Braun DK; Erickson JS; Berclaz PY; Banerjee S; Heffernan MP; Carlier H
    J Rheumatol; 2016 Feb; 43(2):289-97. PubMed ID: 26669919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors.
    Genovese MC; Greenwald M; Cho CS; Berman A; Jin L; Cameron GS; Benichou O; Xie L; Braun D; Berclaz PY; Banerjee S
    Arthritis Rheumatol; 2014 Jul; 66(7):1693-704. PubMed ID: 24623718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of ixekizumab in patients with PsA and previous inadequate response to TNF inhibitors: week 52 results from SPIRIT-P2.
    Genovese MC; Combe B; Kremer JM; Tsai TF; Behrens F; Adams DH; Lee C; Kerr L; Nash P
    Rheumatology (Oxford); 2018 Nov; 57(11):2001-2011. PubMed ID: 30053162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1.
    Mease PJ; van der Heijde D; Ritchlin CT; Okada M; Cuchacovich RS; Shuler CL; Lin CY; Braun DK; Lee CH; Gladman DD;
    Ann Rheum Dis; 2017 Jan; 76(1):79-87. PubMed ID: 27553214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The efficacy and safety of tocilizumab combined with disease-modifying anti-rheumatoid drugs in the treatment of active rheumatoid arthritis: a multi-center, randomized, double-blinded, placebo-controlled trial].
    Shi Q; Zhao Y; Bao CD; Li XF; Huang F; Zhu P; Li ZG; Gu JR; Zhang ZY; Zhao DB; Zhao SL; Jiang QD; Tian J; Zhang FC
    Zhonghua Nei Ke Za Zhi; 2013 Apr; 52(4):323-9. PubMed ID: 23925361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis.
    Gordon KB; Leonardi CL; Lebwohl M; Blauvelt A; Cameron GS; Braun D; Erickson J; Heffernan M
    J Am Acad Dermatol; 2014 Dec; 71(6):1176-82. PubMed ID: 25242558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to an anti-TNF (tumour necrosis factor) biologic therapy: a randomized, controlled trial.
    Taylor PC; Saurigny D; Vencovsky J; Takeuchi T; Nakamura T; Matsievskaia G; Hunt B; Wagner T; Souberbielle B;
    Arthritis Res Ther; 2019 Apr; 21(1):101. PubMed ID: 30999929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
    Furst DE; Schiff MH; Fleischmann RM; Strand V; Birbara CA; Compagnone D; Fischkoff SA; Chartash EK
    J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of switching from adalimumab to sarilumab in patients with rheumatoid arthritis in the ongoing MONARCH open-label extension.
    Burmester GR; Strand V; Rubbert-Roth A; Amital H; Raskina T; Gómez-Centeno A; Pena-Rossi C; Gervitz L; Thangavelu K; St John G; Boklage S; Genovese MC
    RMD Open; 2019; 5(2):e001017. PubMed ID: 31673415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients who could not receive methotrexate: 52-week results from an open-label extension of the HIKARI study.
    Tanaka Y; Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Eguchi K; Watanabe A; Origasa H; Shoji T; Miyasaka N; Koike T
    Mod Rheumatol; 2014 Sep; 24(5):725-33. PubMed ID: 24372225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy.
    Genovese MC; Schiff M; Luggen M; Becker JC; Aranda R; Teng J; Li T; Schmidely N; Le Bars M; Dougados M
    Ann Rheum Dis; 2008 Apr; 67(4):547-54. PubMed ID: 17921185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Randomized Phase IIb Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis.
    Weinblatt ME; McInnes IB; Kremer JM; Miranda P; Vencovsky J; Guo X; White WI; Ryan PC; Godwood A; Albulescu M; Close D; Burmester GR
    Arthritis Rheumatol; 2018 Jan; 70(1):49-59. PubMed ID: 28941039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and Efficacy of Baricitinib Through 128 Weeks in an Open-label, Longterm Extension Study in Patients with Rheumatoid Arthritis.
    Keystone EC; Genovese MC; Schlichting DE; de la Torre I; Beattie SD; Rooney TP; Taylor PC
    J Rheumatol; 2018 Jan; 45(1):14-21. PubMed ID: 28811354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: 52-week results from an open-label extension of the J-RAPID study.
    Tanaka Y; Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Eguchi K; Watanabe A; Origasa H; Shoji T; Miyasaka N; Koike T
    Mod Rheumatol; 2014 Sep; 24(5):734-43. PubMed ID: 24593170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study.
    Genovese MC; Fleischmann R; Furst D; Janssen N; Carter J; Dasgupta B; Bryson J; Duncan B; Zhu W; Pitzalis C; Durez P; Kretsos K
    Ann Rheum Dis; 2014 Sep; 73(9):1607-15. PubMed ID: 24641941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52-week Results from a Phase III Study (SPIRIT-P1).
    van der Heijde D; Gladman DD; Kishimoto M; Okada M; Rathmann SS; Moriarty SR; Shuler CL; Carlier H; Benichou O; Mease PJ
    J Rheumatol; 2018 Mar; 45(3):367-377. PubMed ID: 29247148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Longterm Safety and Efficacy of Subcutaneous Tocilizumab Monotherapy: Results from the 2-year Open-label Extension of the MUSASHI Study.
    Ogata A; Amano K; Dobashi H; Inoo M; Ishii T; Kasama T; Kawai S; Kawakami A; Koike T; Miyahara H; Miyamoto T; Munakata Y; Murasawa A; Nishimoto N; Ogawa N; Ojima T; Sano H; Shi K; Shono E; Suematsu E; Takahashi H; Tanaka Y; Tsukamoto H; Nomura A;
    J Rheumatol; 2015 May; 42(5):799-809. PubMed ID: 25834203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. One-year efficacy and safety results of secukinumab in patients with rheumatoid arthritis: phase II, dose-finding, double-blind, randomized, placebo-controlled study.
    Genovese MC; Durez P; Richards HB; Supronik J; Dokoupilova E; Aelion JA; Lee SH; Codding CE; Kellner H; Ikawa T; Hugot S; Ligozio G; Mpofu S
    J Rheumatol; 2014 Mar; 41(3):414-21. PubMed ID: 24429175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors.
    Genovese MC; Fleischmann RM; Greenwald M; Satterwhite J; Veenhuizen M; Xie L; Berclaz PY; Myers S; Benichou O
    Ann Rheum Dis; 2013 Sep; 72(9):1461-8. PubMed ID: 23268367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tocilizumab in patients with active rheumatoid arthritis and inadequate responses to DMARDs and/or TNF inhibitors: a large, open-label study close to clinical practice.
    Bykerk VP; Ostör AJ; Alvaro-Gracia J; Pavelka K; Ivorra JA; Graninger W; Bensen W; Nurmohamed MT; Krause A; Bernasconi C; Stancati A; Sibilia J
    Ann Rheum Dis; 2012 Dec; 71(12):1950-4. PubMed ID: 22615456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.